Varian announced today that it received FDA 510(k) clearance for its TrueBeam and Edge radiotherapy systems with HyperSight imaging.
The Siemens Healthineers company designed HyperSight to empower clinicians to accurately tailor treatments to individual patients. This helps improve patient outcomes, thanks to new capabilities and workflows across the company’s linear accelerators.
HyperSight allows clinicians to acquire high-quality images during a patient’s daily course of radiation treatments. It helps to improve the ability to target tumor volumes more precisely and spare healthy tissue for patients undergoing radiation therapy.
Adding HyperSight to the Varian line of linear accelerators means the company’s portfolio can produce images that deliver the Hounsfield Unit (HU) accuracy necessary for treatment planning directly on the acquired conebeam CT (CBCT) images. This enables the use of the technology for offline adaptive planning to adjust for anatomical changes. These adjustments can take place over the course of treatment without the need for a trip to a separate CT scanner.
On the TrueBeam and Edge platforms, HyperSight acquires images for all anatomical sites with a 50% faster gantry rotation. Varian said it significantly reduces acquisition time. This could minimize patient discomfort and anxiety with less time on the treatment table.
“As a Siemens Healthineers company, we are pioneering innovative solutions to advance radiotherapy and connect the power of imaging, both inside and outside the treatment room,” said Arthur Kaindl, head of Varian. “We are excited to expand HyperSight imaging technology to our TrueBeam and Edge platforms and further collaborate with our clinical partners to provide an integrated portfolio that connects the dots along the cancer care continuum.”